Conventional treatment of peripheral T-cell lymphoma: the Asian perspective


Published: June 10, 2009
Abstract Views: 151
PDF: 378
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Lymphoma Study Group of Japanese pathologists reviewed 3,194 cases of malignant lymphoma in Japan, according to the WHO Classification.1 Sixty-nine percent of cases were of B-cell lymphoma, 25% were of T- or NK-cell lymphoma and 4% of Hodgkin lymphoma. Among T- or NK-cell lymphoma, human T-cell leukemia virus type-I (HTLV-I)-associated adult T-cell leu ke mia-lymphoma (ATL) was the most frequent subtype (7.5%), PTCL, unspecified was the second (6.7%), and the relative frequency of nasal and nasal-type NK/T-cell lymphoma (2.6%) was higher than Western countries but less than other East Asian countries including Korea and Hong Kong.

Supporting Agencies


Tobinai, K. (2009). Conventional treatment of peripheral T-cell lymphoma: the Asian perspective. Hematology Meeting Reports (formerly Haematologica Reports), 2(13). https://doi.org/10.4081/hmr.v2i13.478

Downloads

Citations